Legend Biotech vs TG Therapeutics
LEGN and TGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LEGN and TGTX compare
TG Therapeutics grew revenue faster over the last twelve months (76.1% versus 59.5% for Legend Biotech).
TG Therapeutics scores higher on the StockData Score (9 against 3 for Legend Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LEGN | TGTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $9.6B |
| Share price | $16.11 | $62.71 |
| Change, 1 year | −46.8% | 102% |
| Change, 5 years | −70.2% | 162% |
| Beta (5Y) | 0.80 | 0.47 |
| Employees | 2,900 | 399 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 4 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.9× |
| P/S | – | 12.0× |
| P/B | – | 15.9× |
| EV/EBITDA | – | 71.3× |
| P/FCF | – | 552× |
| FCF yield | – | 0.18% |
| Fair value | – | $60.66 |
| Margin of safety | – | −3.4% |
| Growth | ||
| Revenue growth (TTM) | 59.5% | 76.1% (better) |
| Revenue growth, 5Y average | 68.8% | 427% (better) |
| Net income growth (TTM) | – | 630% |
| EPS growth (TTM) | – | 641% |
| Profitability | ||
| Gross margin | 57.2% | 82.4% (better) |
| Operating margin | −4.3% | 17.1% (better) |
| Net margin | – | 55.2% |
| FCF margin | −9.6% | 2.2% (better) |
| Return on equity | – | 100% |
| Return on invested capital | – | 27.8% |
| Financial health | ||
| Debt / equity | – | 1.23 |
| Net debt / EBITDA | – | 0.98 |
| Interest coverage | −2.5× | 3.6× (better) |
| Current ratio | 3.04 | 4.27 (better) |
| Altman Z-score | – | 6.07 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.9% |
| Shareholder yield | – | 1.9% |
| Ownership | ||
| Held by institutions | 28.4% | 72.6% |
| Held by insiders | 0.50% | 16.1% |
| Insider net buying, 12 months | −$384K | −$275K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 22.4% |
Go deeper
- LEGN stock overview
- LEGN income statement
- LEGN valuation and score
- TGTX stock overview
- TGTX income statement
- TGTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.